BIAFW
bioAffinity Technologies, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$0.70
+78.74%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.9M | 6.2M | 9.4M | 2.5M | 4.8K |
| Cost of Revenue | 8.2M | 4.7M | 6.0M | 1.7M | 467.00 |
| Gross Profit | (2.3M) | 1.4M | 3.4M | 791.6K | 4.3K |
| Operating Expenses | |||||
| R&D Expense | 1.9M | 2.1M | 1.8M | 1.7M | 1.5M |
| SG&A Expense | 11.3M | 9.9M | 9.9M | 6.8M | 2.5M |
| General & Admin Expense | 2.9M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (3.2M) | — | 606.0K | 249.6K | 10.2K |
| Total Operating Expenses | 10.0M | 12.0M | 12.3M | 8.8M | 4.0M |
| Cost and Expenses | 18.3M | 16.7M | 18.3M | 10.5M | 4.0M |
| Operating Income (EBIT) | (12.4M) | (10.6M) | (9.0M) | (8.0M) | (4.0M) |
| Non-Operating | |||||
| Interest Income | 34.2K | 23.4K | 17.6K | 122.1K | 46.7K |
| Interest Expense | 44.8K | 44.4K | 92.5K | 37.1K | 2.5M |
| Net Interest Income | (10.6K) | (21.0K) | (74.9K) | 85.0K | (2.5M) |
| Other Non-Op Income/Expense | (2.8M) | (4.3M) | (75.3K) | 57.2K | (4.1M) |
| Non-Operating Income (excl Interest) | 2.8M | 4.2M | (17.7K) | (94.3K) | 1.6M |
| EBT (Pre-Tax Income) | (15.2M) | (14.9M) | (9.0M) | (7.9M) | (8.2M) |
| Income Tax Expense | 6.4K | 44.0K | 11.7K | 21.0K | 2.5K |
| Bottom Line | |||||
| Net Income | (15.2M) | (14.9M) | (9.0M) | (7.9M) | (8.2M) |
| Earnings from Cont. Ops | (15.2M) | (14.9M) | (9.0M) | (7.9M) | (8.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (15.2M) | (14.9M) | (9.0M) | (7.9M) | (8.2M) |
| Per Share | |||||
| Basic EPS | ($120.15) | ($129.90) | ($337.50) | ($409.50) | ($814.50) |
| Diluted EPS | ($120.15) | ($129.90) | ($337.50) | ($409.50) | ($814.50) |
| Revenue Per Share | $16.93 | $53.70 | $347.31 | $130.25 | $0.48 |
| Shares | |||||
| Basic Shares Outstanding | 348450 | 114739 | 26956 | 19440 | 9998 |
| Diluted Shares Outstanding | 348450 | 114739 | 26956 | 19440 | 9998 |
| Profitability Metrics | |||||
| EBITDA | (14.7M) | (14.3M) | (8.3M) | (7.6M) | (5.6M) |
| D&A | 413.1K | 504.8K | 605.6K | 249.6K | 10.2K |
| EBIT | (15.1M) | (14.8M) | (8.9M) | (7.9M) | (5.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026